Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of BI 1358894 Formulations
NCT03892616Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bi 1358894 in major depressive disorder (MDD), borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) (12 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Measured Concentration of BI 1358894 in Plasma and Area Under the Concentration-time Curve of BI 1358894 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point. Started Apr 2019; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)borderline personality disorder (BPD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03892616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892616.